Lee's Pharmaceutical Files HKEX Return Disclosing Share Buyback for CancellationPUBT·Nov 10, 2026 at 12:00 AM00950+0.50%
Lee's Pharmaceutical Discloses Share Buyback for Cancellation in HKEX FilingPUBT·Nov 6, 2026 at 10:18 AM00950+0.50%
Lee's Pharma files HKEX next-day return disclosing share buyback for cancellationPUBT·Nov 5, 2026 at 10:39 AM00950+0.50%
Hong Kong's Consumer Divide: Vitasoy Stumbles as 361 Degrees and Pharma OutperformGlobal Report·Oct 22, 2026 at 09:14 AM00345+1.43%01361-0.10%
REG - Syquant Capital Irish Continental - Form 8.3:IR5B IDLondon Stock Exchange·Oct 2, 2026 at 02:30 PM00950+0.50%
Three Days Left Until Lee's Pharmaceutical Holdings Limited (HKG:950) Trades Ex-DividendSimplywall·Sep 21, 2026 at 02:02 AM00950+0.50%
Lee’s Pharm signs exclusive OC-3 cancer drug licensing deal with 1cBio for China, Hong Kong, Taiwan, Southeast Asia marketsPUBT·Sep 9, 2026 at 02:34 PM00950+0.50%
Lee’s Pharmaceutical declares interim dividend of HKD 0.035 a sharePUBT·Aug 31, 2026 at 09:57 AM00950+0.50%
Lee’s Pharmaceutical FY26 H1 profit attributable to owners climbs 41.4% to HK$ 95.01 million; revenue rises 14.6% to HK$ 796.57 millionPUBT·Aug 31, 2026 at 09:47 AM00950+0.50%
Lee's Pharma sees H1 net profit attributable to shareholders at HK$85 million-HK$95 millionPUBT·Aug 26, 2026 at 01:08 PM00950+0.50%